iifl-logo

Jubilant Pharmova Ltd Key Ratios

1,124.6
(-1.32%)
Sep 11, 2025|12:00:00 AM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

FINANCIALS

Y/e 31 MarMar-2021Mar-2020Mar-2018Mar-2017

Growth matrix (%)

Revenue growth

-33.38

21.76

28.25

1.95

Op profit growth

-28.27

28.23

12.86

7.88

EBIT growth

-30.49

34.04

5.98

18.08

Net profit growth

-6.94

39.73

11.66

46.91

Profitability ratios (%)

OPM

22.89

21.26

20.19

22.95

EBIT margin

17.46

16.74

15.2

18.4

Net profit margin

13.7

9.81

8.55

9.82

RoCE

11.51

16.71

14.95

14.15

RoNW

4.03

4.63

4.27

4.49

RoA

2.25

2.44

2.1

1.88

Per share ratios (₹)

EPS

52.49

56.39

40.72

36.89

Dividend per share

5

5

3

3

Cash EPS

30.56

27.38

14.61

18.25

Book value per share

297.64

351.77

262.3

220.61

Valuation ratios

P/E

12.96

3.82

17.89

18.78

P/CEPS

22.25

7.88

49.84

37.96

P/B

2.28

0.61

2.77

3.14

EV/EBIDTA

9.19

3.69

10.65

11.9

Payout (%)

Dividend payout

0

0

7.26

8.11

Tax payout

-33.73

-25.07

-26.15

-22.09

Liquidity ratios

Debtor days

63.23

48.32

51.85

60.89

Inventory days

89.02

64.52

63.4

75.45

Creditor days

-65.15

-58.27

-59.85

-57.53

Leverage ratios

Interest coverage

-5.78

-5.33

-4.02

-3.16

Net debt / equity

0.45

0.6

0.78

1.04

Net debt / op. profit

1.54

1.75

2.12

2.66

Cost breakup (₹)

Material costs

-25.18

-34.3

-38.15

-34.11

Employee costs

-31.53

-23.24

-20.69

-21

Other costs

-20.38

-21.18

-20.94

-21.93

Jubilant Pharmo : related Articles

Jubilant Pharmova to sale API business to Jubilant Biosys

The API division posted a turnover of ₹609 Crore for the financial year ended March 2025. This was 8.35% of the company’s consolidated revenue.

13 Jun 2025|12:29 PM
Read More
Top Stocks for Today - 13th June 2025

Here are some of the stocks that may see significant price movement today: Torrent Power, DCM Shriram, Jubilant Pharmova, etc.

13 Jun 2025|06:37 AM
Read More
Jubilant Pharmova Passes FDA Audit, Expands R&D with Pierre Fabre

This FDA audit confirms compliance with regulatory standards, enhancing the credibility of Jubilant's operations in the United States.

26 Sep 2024|07:42 PM
Read More
FDA Issues VAI Status to Jubilant HollisterStier's Washington Facility

Jubilant Pharmova Ltd has gained a total of 126% in the last one year, and almost 75% gain since the beginning of the year.

11 Sep 2024|11:23 AM
Read More
Top 10 stocks for today – 11th September, 2024

Here are some of the stocks that may see significant price movement today: Tata Motors, Reliance Industries, IREDA, etc.

11 Sep 2024|09:23 AM
Read More
Jubilant Pharmova arm to pick up 80% stake in Pierre Fabre’s centre

Drug company Jubilant Pharmova Ltd will acquire an 80% stake in Pierre Fabre Laboratories' Research & Development Centre in Saint Julien, France.

19 Aug 2024|01:36 PM
Read More
Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.